Stoke Therapeutics Advances Zorevunersen Toward FDA Submission with Phase 3 Data Expected in 2027 — Stoke Therapeutics, Inc.

Event summary

Stoke Therapeutics completed enrollment of 162 patients in the Phase 3 EMPEROR study for zorevunersen, with data readout anticipated in Q3 2027.
The company plans to initiate a rolling NDA submission for zorevunersen in Q1 2027 following a pre-NDA meeting with the FDA in H2 2026.
Stoke reported $420 million in cash reserves, sufficient to fund operations through early 2028 and potential U.S. launch of zorevunersen.
Phase 1 dose escalation for STK-002 in Autosomal Dominant Optic Atrophy (ADOA) is underway, with initial data expected in H1 2027.

The big picture

Stoke Therapeutics is positioning itself as a leader in RNA medicine, with zorevunersen poised to become the first disease-modifying treatment for Dravet syndrome. The company's strategic focus on rare genetic diseases and its collaboration with Biogen underscore its ambition to expand into other haploinsufficient conditions. The upcoming regulatory milestones will be critical in determining Stoke's long-term growth trajectory.

What we're watching

Regulatory Pathway: The success of the rolling NDA submission hinges on the Phase 3 EMPEROR data and FDA alignment during the pre-NDA meeting.
Pipeline Progress: The pace at which STK-002 advances through Phase 1 will determine Stoke's ability to diversify its therapeutic portfolio beyond Dravet syndrome.
Financial Runway: Whether the $420 million cash position will be sufficient to support operations and potential commercialization of zorevunersen through early 2028.